Barbui T et al. Second versus first wave of COVID-19 in patients with MPN. Leukemia 2022;36(3):897-900. Abstract
Gupta V et al. Safety and tolerability of fedratinib (FEDR), an oral inhibitor of Janus kinase 2 (JAK2), in patients with intermediate- or high-risk myelofibrosis (MF) previously treated with ruxolitinib (RUX): Results from the Phase 3b FREEDOM trial. ASH 2021;Abstract 389.
Hargreaves R et al. Diagnostic and management strategies for myeloproliferative neoplasm-unclassifiable (MPN-U): An international survey of contemporary practice. Curr Res Transl Med 2022;[Online ahead of print]. Abstract
Harrington P et al. Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients. Cancer Cell 2021;39(12):1654. Abstract
Harrison CN et al. Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: Phase II safety and efficacy. J Clin Oncol 2022;[Online ahead of print]. Abstract
Harrison CN et al. Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis. ASH 2021;Abstract 3649.
Khan A et al. Low-dose splenic irradiation in conjunction with ruxolitinib to provide symptomatic relief in heavily treated, advanced stage myelofibrosis: A case series from a UK tertiary referral center. Hemasphere 2021;5(7):e611. Abstract
Mascarahenas J et al. A retrospective head-to-head comparison between pacritinib and ruxolitinib in patients with myelofibrosis and moderate to severe thrombocytopenia. ASH 2021;Abstract 3639.
Mascarahenas J et al. Safety analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia. ASH 2021;Abstract 3640.
McLornan DP et al. Current and future status of JAK inhibitors. Lancet 2021;398(10302):803-16. Abstract
McLornan DP et al. How I manage myeloproliferative neoplasm-unclassifiable: Practical approaches for 2022 and beyond. Br J Haematol 2022;[Online ahead of print]. Abstract
Mesa RA et al. INDEPENDENCE: A phase 3 study of efficacy and safety of luspatercept versus placebo in patients with myeloproliferative neoplasm-associated myelofibrosis on JAK2 inhibitor therapy and requiring red blood cell transfusions. ASH 2021;Abstract 1490.
Palmer JM et al. The impact of pacritinib on myelofibrosis symptoms in patients with moderate and severe thrombocytopenia: A retrospective analysis of patients in the Persist-2 study. ASH 2021;Abstract 3628.
Pemmaraju N et al. Addition of navitoclax to ruxolitinib mediates responses suggestive of disease modification in patients with myelofibrosis previously treated with ruxolitinib monotherapy. AACR 2022;Abstract LB108/2.
Ross DM et al. Adore: A randomized, open-label, phase 1/2 open-platform study evaluating safety and efficacy of novel ruxolitinib combinations in patients with myelofibrosis. ASH 2021;Abstract 1489.
Saha C et al. Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond. Blood Rev 2022;[Online ahead of print]. Abstract
Vacchani P et al. Disease modification in myelofibrosis: An elusive goal? J Clin Oncol 2022;40(11):1147-55. Abstract
Verstovsek S et al. Does early intervention in myelofibrosis impact outcomes? A pooled analysis of the Comfort I and II studies. ASH 2021;Abstract 1505.
Verstovsek S et al. Real-world survival of US patients with intermediate- to high-risk myelofibrosis: Impact of ruxolitinib approval. Ann Hematol 2022;101(1):131-7. Abstract
Verstovsek S et al. Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia. Haematologica 2021;[Online ahead of print]. Abstract